What To Know
- I am appreciative of the clinical efforts being made by leading clinicians to substantiate its clinical value and look forward to announcing the highly anticipated results of our IDE study in the U.
- Positive results from a single-center, prospective observational study of the Surfacer System demonstrating a 100% success rate in all patients will be presented on April 16th from 2.
Surfacer Inside-Out Access Catheter System: Bluegrass Vascular Technologies announced today events taking place at the Charing Cross (CX) International Symposium this week in London, United Kingdom on April 15-18, 2019. Leading clinicians will discuss experience with the Surfacer® Inside-Out® Access Catheter System.
The Surfacer Inside-Out Access Catheter System is indicated for obtaining central venous access to facilitate catheter insertion in patients with diminished upper body access. Bluegrass Vascular is a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures.
Positive results from a single-center, prospective observational study of the Surfacer System demonstrating a 100% success rate in all patients will be presented on April 16th from 2:42 – 2:47 pm BST by Tobias Steinke, M.D., Chief of Vascular and Endovascular Surgery, Schön Klinik, Düsseldorf, Germany. The session titled “The Surfacer System – a single-center prospective observation study in central venous occlusion to demonstrate safety and efficacy” adds to the growing body of strong clinical evidence supporting the Surfacer System during routine commercial use.
“I look forward to sharing the compelling clinical results assessing the safety and efficacy of the Surfacer Inside-Out Access Catheter System as a viable treatment for central venous obstructions,” stated Dr. Steinke, an investigator of the SAVE Post-Market Registry and presenter of the study’s results at the 2019 Leipzig Interventional Course (LINC). “The Surfacer System continues to be an important tool used to reliably gain access and guard against the damaging and often deadly progression of this disease frequently experienced by patients in my clinical practice.”
“The Surfacer System is an innovative approach to a long-standing problem that achieves sustainable access and delivery of life-saving treatments to patients, such as those requiring hemodialysis,” stated James Gilbert, M.D., Consultant Transplant & Vascular Access Surgeon at Oxford University Hospitals NHS Foundation Trust. “I look forward to expanding upon the extensive clinical capabilities of the Surfacer System in this week’s Masterclass at Charing Cross.”
Gabriele Niederauer, Ph.D., CEO and President of Bluegrass Vascular, commented, “This is an exciting time for our company and for patients everywhere suffering from the devastating effects of chronically occluded veins. I am appreciative of the clinical efforts being made by leading clinicians to substantiate its clinical value and look forward to announcing the highly anticipated results of our IDE study in the U.S.”
The Surfacer System will also be highlighted during the following educational sessions:
- “Central Occlusion Vascular Access Masterclass ‘Inside-Out”” presented by Dr. Gilbert on Wednesday, April 17th from 9:00am – 4:00pm BST.
- The “CX Vascular Access Workshop” demonstrated by Gürkan Sengölge, M.D., Medical University of Vienna, Department of Medicine III, Division of Nephrology and Dialysis on Thursday, April 18th from 10:00am – 4:00pm BST.
The Surfacer System is CE-Mark approved and nearing completion of its pre-market investigational device exempt (IDE) study, SAVE-US (Surfacer® System to Facilitate Access in VEnous Occlusions – United States).
